Bromazepam
As of the edition of 20 October 2026, Bromazepam is a small molecule: marketed, first approved in 1974 (CH); acts on GABRA2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Small molecule
- Brand name
- Lexotanil
- First approved
- 15 July 1974 (CH)
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- MOKSHA8 BRASIL INDUSTRIA E COMERCIO DE MEDICAMENTOS LTDA; 3 holders in all
- Registered trials
- 1, 1 stopped early
- Disease areas
- Mental health; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| GABRA2 | Gamma-aminobutyric acid receptor subunit alpha-2 | P47869 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 1 |